Skip to main content
OpenTrials
Completed

NCT Number: NCT01215279

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Disease Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Tract Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Site, Rousse, Bulgaria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female of non-child bearing potential. Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
  • Between 40 and 80 years of age at Visit 1
  • Clinical diagnosis of COPD (GOLD stage 2 or 3)
  • FEV1/FVC <70% and FEV1 between 30 and 80% of the predicted normal post-bronchodilator (GOLD stage 2 or 3)
  • Current or ex-smokers

Exclusion criteria

  • Any clinically significant disease or disorder (including history of abnormal immune function) which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
  • Any lung disease other than COPD, recent respiratory infections which have not resolved fully, active tuberculosis or at risk of reactivation of tuberculosis.
  • Any abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability to take part or influence the results of the study
  • Immunisation with a live vaccine within 3 months or other vaccination within 30 days before planned start of treatment
  • Worsening of COPD symptoms within 4 weeks prior to start of study needing hospitalisation, oral steroids or antibiotics.

Treatment and study plan

AZD2423

Drug

100 mg oral treatment once daily for 28 days

Placebo to AZD2423

Drug

Oral treatment once daily for 28 days

Primary outcomes

  1. Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes

    Time frame: Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)

    Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points

  2. Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)

    Number of participants with clinically significant changes in vital signs assessed at all the listed time points

  3. Number of Participants With Clinically Significant Changes in ECG Variables

    Time frame: Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)

    Number of participants with clinically significant changes in ECG variables assessed at all the listed time points

  4. Number of Participants With Clinically Significant Changes in Physical Examination

    Time frame: Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)

    Number of participants with clinically significant changes in physical examination assessed at all the listed time points

  5. Monocytes at Baseline

    Time frame: Day 1

    Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)

  6. Monocytes at End of Treatment

    Time frame: week 4

    Monocyte count in peripheral blood at end of treatment (4 weeks)

  7. Monocytes at Follow-up

    Time frame: week 5 (follow-up)

    Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)

Secondary outcomes

  1. Morning FEV1 at Baseline

    Time frame: Average of 10 days of pre-treatment measurements (day -10 to -1)

    Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.

  2. Morning FEV1 During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.

  3. Evening FEV1 at Baseline

    Time frame: Average of 10 days of pre-treatment measurements (day -10 to -1)

    Measurement conducted by patient in evening.

  4. Evening FEV1 During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    Measurement conducted by patient in evening.

  5. Morning Peak Expiratory Flow (PEF) at Baseline

    Time frame: Average of 10 days of pre-treatment measurements (day -10 to -1)

    Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.

  6. Morning PEF During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.

  7. Evening PEF at Baseline

    Time frame: Average of 10 days of pre-treatment measurements (day -10 to -1)

    Measurement conducted by patient in evening.

  8. Evening PEF During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    Measurement conducted by patient in evening.

  9. Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score at Baseline

    Time frame: Average of 7 days of pre-treatment measurements (day -7 to -1)

    The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation). Baseline is the mean value over the 7 days prior to randomisation.

  10. EXACT Total Score During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation).

  11. Breathlessness, Cough and Sputum Scale (BCSS) (Evening) Total Score at Baseline

    Time frame: Average of 10 days of pre-treatment measurements (day -10 to -1)

    The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units. Baseline is mean of 10 days prior to treatment.

  12. BCSS (Evening) Total Score During Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units.

  13. Rescue Medication Use During the Last 7 Days of Treatment

    Time frame: Average of the last 7 days of treatment (week 4)

    Number of inhalations of short acting β2 agonist (SABA) or short acting muscarinic antagonist (SAMA) per day.

  14. St George's Respiratory Questionnaire for COPD (SGRQ) Total Score at Baseline

    Time frame: Day 1

    The SGRQ-C includes 40 questions in 3 domains: Symptoms (distress due to respiratory symptoms, 7 questions), Activity (disturbance of physical activity, 13 questions), Impacts (overall impact on daily life and well-being, 20 questions). Scores are expressed as a percentage. Baseline is Day 1.

  15. SGRQ Total Score at End of Treatment

    Time frame: week 4

    Decrease in score represents improved Quality of Life; increase represents deteriorated Quality of Life. An increase or decrease of 4 or more percent units is judged as the Minimal Clinically Important Difference.

  16. CCL2 (Chemokine Ligand for CCR2b Receptor) Concentration in Plasma at Baseline

    Time frame: Day 1

    Baseline = Day 1 = Visit 2

  17. CCL2 Concentration in Plasma at End of Treatment

    Time frame: week 4

    End of treatment = 4 weeks = Visit 6

  18. Serum Amyloid-A (SAA) Concentration in Plasma at Baseline

    Time frame: Day 1

    Baseline = Day 1 = Visit 2

  19. SAA Concentration in Plasma at End of Treatment

    Time frame: week 4

    End of treatment = 4 weeks = Visit 6

  20. Areaa Under the Curve From 0 to 24 Hours (AUC 0-24), Population Pharmacokinetic Evaluation of AZD2423 at Steady State

    Time frame: 2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4

    PK-model: 1-compartment population model with first order absorption. AUC was estimated at steady state

  21. Cmax, Population Pharmacokinetic Evaluation of AZD2423 at Steady State

    Time frame: 2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4

    PK-model: 1-compartment population model with first order absorption. Cmaxwas estimated at steady state

  22. Time to Reach Maximum Concentration (Tmax) Population Pharmacokinetic Evaluation of AZD2423 at Steady State

    Time frame: 2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4

    PK-model: 1-compartment population model with first order absorption. tmax was estimated at steady state

  23. Apparent Volume of Distribution at Steady State (Vss/F) Population Pharmacokinetic Evaluation of AZD2423 at Steady State

    Time frame: 2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4

    PK-model: 1-compartment population model with first order absorption. (Vss/F) was estimated at steady state

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Oct 6, 2010
Registry last updated
Oct 23, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.